Anna M Wu

List of Publications by Year
in descending order

178 papers	19,084 citations	23500 58 h-index	11581 135 g-index
184 all docs	184 docs citations	184 times ranked	21015 citing authors

#	Article	IF	Citations
1	Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics. Science, 2005, 307, 538-544.	6.0	7,371
2	Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology, 2005, 23, 1137-1146.	9.4	978
3	Particle Size, Surface Coating, and PEGylation Influence the Biodistribution of Quantum Dots in Living Mice. Small, 2009, 5, 126-134.	5.2	418
4	Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Engineering, Design and Selection, 2006, 19, 391-400.	1.0	371
5	The complete nucleotide sequence of the tryptophan operon of Escherichia coli. Nucleic Acids Research, 1981, 9, 6647-6668.	6.5	366
6	Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nature Communications, 2017, 8, 1811.	5.8	360
7	Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nature Methods, 2007, 4, 641-643.	9.0	277
8	An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Research, 2016, 76, 73-82.	0.4	265
9	Antibodies and Antimatter: The Resurgence of Immuno-PET. Journal of Nuclear Medicine, 2009, 50, 2-5.	2.8	227
10	Solution-Phase Surface Modification in Intact Poly(dimethylsiloxane) Microfluidic Channels. Analytical Chemistry, 2006, 78, 5543-5551.	3.2	212
11	High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8495-8500.	3.3	196
12	microPET-Based Biodistribution of Quantum Dots in Living Mice. Journal of Nuclear Medicine, 2007, 48, 1511-1518.	2.8	182
13	Antibody Vectors for Imaging. Seminars in Nuclear Medicine, 2010, 40, 167-181.	2.5	182
14	Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology: an International Journal of Immunological Engineering, 1996, 2, 21-36.	2.4	181
15	Advances in Immunoâ€“Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology. Journal of Clinical Oncology, 2012, 30, 3884-3892.	0.8	176
16	In vivo imaging with antibodies and engineered fragments. Molecular Immunology, 2015, 67, 142-152.	1.0	173
17	First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of Nuclear Medicine, 2020, 61, 512-519.	2.8	170
18	124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. Journal of Nuclear Medicine, 2003, 44, 1962-9.	2.8	167

#	Article	IF	Citations
19	The Soluble Serum Protein Gas6 Bridges Virion Envelope Phosphatidylserine to the TAM Receptor Tyrosine Kinase Axl to Mediate Viral Entry. Cell Host and Microbe, 2011, 9, 286-298.	5.1	165
20	Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging. Cancer Research, 2005, 65, 5907-5916.	0.4	158
21	Engineered antibody fragments for immuno-PET imaging of endogenous CD8 ⁺ T cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1108-1113.	3.3	148
22	Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Research, 2005, 65, 622-31.	0.4	144
23	Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Research, 2003, 63, 1160-5.	0.4	140
24	Engineered antibodies for molecular imaging of cancer. Methods, 2014, 65, 139-147.	1.9	139
25	Antibodies for Molecular Imaging of Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 191-197.	1.0	132
26	Concerted strand exchange and formation of Holliday structures by E. coli RecA protein. Cell, 1981, 25, 507-516.	13.5	130
27	Homologous pairing and topological linkage of DNA molecules by combined action of E. coli recA protein and topoisomerase I. Cell, 1981, 24, 213-223.	13.5	128
28	A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn). Annals of Biomedical Engineering, 2005, 33, 1640-1652.	1.3	128
29	Tandem termination sites in the tryptophan operon of Escherichia coli.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 2913-2917.	3.3	120
30	First-in-Human Imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine, 2016, 57, 1858-1864.	2.8	116
31	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. OncoImmunology, 2018, 7, e1380764.	2.1	111
32	CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: Implications for cellular immunotherapy of CD20+ malignancy. Biology of Blood and Marrow Transplantation, 1998, 4, 75-83.	2.0	105
33	Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. Journal of Nuclear Medicine, 2015, 56, 1258-1264.	2.8	104
34	Human T Lymphocyte Genetic Modification with Naked DNA. Molecular Therapy, 2000, 1, 49-55.	3.7	102
35	Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Engineering, Design and Selection, 2004, 17, 21-27.	1.0	102
36	Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody:â€‰ Comparison to Radioiodinated Fragments. Bioconjugate Chemistry, 2001, 12, 220-228.	1.8	97

#	Article	IF	Citations
37	Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunology, Immunotherapy, 2000, 49, 243-252.	2.0	96
38	PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. Journal of Nuclear Medicine, 2007, 48, 304-10.	2.8	92
39	Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer. Clinical Cancer Research, 2004, 10, 5014-5021.	3.2	86
40	Tailoring antibodies for radionuclide delivery. Expert Opinion on Drug Delivery, 2006, 3, 53-70.	2.4	86
41	Radioiodinated versus Radiometal-Labeled Antiâ€“Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy. Cancer Research, 2007, 67, 718-726.	0.4	86
42	Formation of nascent heteroduplex structures by RecA protein and DNA. Cell, 1982, 30, 37-44.	13.5	85
43	CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clinical Cancer Research, 2018, 24, 4976-4987.	3.2	79
44	A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clinical Cancer Research, 2003, 9, 5842-52.	3.2	79
45	Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Engineering, Design and Selection, 2004, 17, 315-323.	1.0	75
46	Fusion of Gaussia Luciferase to an Engineered Anti-carcinoembryonic Antigen (CEA) Antibody for In Vivo Optical Imaging. Molecular Imaging and Biology, 2007, 9, 267-277.	1.3	73
47	The Crystal Structure of an Anti-CEA scFv Diabody Assembled from T84.66 scFvs in VL-to-VH Orientation: Implications for Diabody Flexibility. Journal of Molecular Biology, 2003, 326, 341-351.	2.0	68
48	Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody. Journal of Immunotherapy, 2007, 30, 396-405.	1.2	68
49	Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas. Journal of Nuclear Medicine, 2009, 50, 1500-1508.	2.8	68
50	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nature Communications, 2020, 11, 660.	5.8	68
51	Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. Journal of Immunological Methods, 2001, 253, 195-208.	0.6	66
52	Photoimmunotherapy Targeting Prostate-Specific Membrane Antigen: Are Antibody Fragments as Effective as Antibodies?. Journal of Nuclear Medicine, 2015, 56, 140-144.	2.8	66
53	Noninvasive Imaging of PSMA in Prostate Tumors with ⁸⁹Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives. Molecular Pharmaceutics, 2014, 11, 3965-3973.	2.3	65
54	Reduction of Kidney Uptake in Radiometal Labeled Peptide Linkers Conjugated to Recombinant Antibody Fragments. Site-Specific Conjugation of DOTA-Peptides to a Cys-Diabody. Bioconjugate Chemistry, 2002, 13, 985-995.	1.8	63

#	Article	IF	Citations
55	Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigenâ€“Expressing Tumors. Clinical Cancer Research, 2008, 14, 7488-7496.	3.2	63
56	Neural Stem Cells as a Novel Platform for Tumor-Specific Delivery of Therapeutic Antibodies. PLoS ONE, 2009, 4, e8314.	1.1	63
57	ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging. Molecular Imaging and Biology, 2017, 19, 599-609.	1.3	61
58	Unwinding associated with synapsis of DNA molecules by recA protein.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 1256-1260.	3.3	60
59	Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Engineering, Design and Selection, 2010, 23, 789-798.	1.0	60
60	Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy, 2003, 5, 131-138.	0.3	57
61	Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nature Protocols, 2006, 1, 2048-2060.	5.5	57
62	A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Molecular Cancer Therapeutics, 2006, 5, 1550-1558.	1.9	57
63	Numerical Selection of Optimal Tumor Imaging Agents with Application to Engineered Antibodies. Cancer Biotherapy and Radiopharmaceuticals, 2001, 16, 25-35.	0.7	56
64	Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Engineering, Design and Selection, 2004, 17, 481-489.	1.0	56
65	Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Engineering, Design and Selection, 2006, 19, 453-460.	1.0	56
66	Transcription termination: Nucleotide sequence at 3' end of tryptophan operon in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America, 1978, 75, 5442-5446.	3.3	55
67	An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1529-1538.	3.3	55
68	ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumor Biology, 2012, 33, 669-677.	0.8	55
69	Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis. Journal of Nuclear Medicine, 2018, 59, 980-985.	2.8	54
70	Positive Progress in ImmunoPETâ€”Not Just a Coincidence. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 253-261.	0.7	53
71	Cys-diabody Quantum Dot Conjugates (ImmunoQdots) for Cancer Marker Detection. Bioconjugate Chemistry, 2009, 20, 1474-1481.	1.8	52
72	Quantitative ImmunoPET of Prostate Cancer Xenografts with ⁸⁹Zr- and ¹²⁴I-Labeled Anti-PSCA A11 Minibody. Journal of Nuclear Medicine, 2014, 55, 452-459.	2.8	51

#	Article	IF	Citations
73	Pre-conditioning modifies the TME to enhance solid tumor CAR TÂcell efficacy and endogenous protective immunity. Molecular Therapy, 2021, 29, 2335-2349.	3.7	51
74	Deletions of distal sequence affect termination of transcription at the end of the tryptophan operon in E. coli. Cell, 1980, 19, 829-836.	13.5	50
75	CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ‹sup›89‹/sup›Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. Journal of Nuclear Medicine, 2021, , jnumed.121.262485.	2.8	49
76	Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Engineering, Design and Selection, 2001, 14, 1025-1033.	1.0	47
77	Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum. New Biotechnology, 2007, 24, 283-291.	2.7	45
78	Engineered Antibody Fragments with Infinite Affinity as Reporter Genes for PET Imaging. Journal of Nuclear Medicine, 2008, 49, 1828-1835.	2.8	45
79	ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization ‹i›In Vivo‹/i›. Clinical Cancer Research, 2017, 23, 7242-7252.	3.2	45
80	An Internet-Based â€œKinetic Imaging Systemâ€•(KIS) for MicroPET. Molecular Imaging and Biology, 2005, 7, 330-341.	1.3	44
81	A Phase I Trial of90Y-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 88-100.	0.7	44
82	Improved Biodistribution and Radioimmunoimaging with Poly(ethylene glycol)-DOTA-Conjugated Anti-CEA Diabody. Bioconjugate Chemistry, 2006, 17, 68-76.	1.8	41
83	Site-Specific, Thiol-Mediated Conjugation of Fluorescent Probes to Cysteine-Modified Diabodies Targeting CD20 or HER2. Bioconjugate Chemistry, 2008, 19, 2527-2534.	1.8	41
84	Anti-CA19-9 Diabody as a PET Imaging Probe for Pancreas Cancer. Journal of Surgical Research, 2011, 170, 169-178.	0.8	41
85	Fluorescent Imageâ€“Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clinical Cancer Research, 2016, 22, 1403-1412.	3.2	40
86	Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Antiâ€“Prostate Stem Cell Antigen Cys-Diabody. Journal of Nuclear Medicine, 2018, 59, 1398-1405.	2.8	40
87	ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Engineering, Design and Selection, 2010, 23, 243-249.	1.0	39
88	Advances in PET Detection of the Antitumor T Cell Response. Advances in Immunology, 2016, 131, 187-231.	1.1	39
89	In vivo NIR-II structured-illumination light-sheet microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	39
90	Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Engineering, Design and Selection, 2008, 22, 209-216.	1.0	38

#	Article	IF	Citations
91	Unexpected Expression Pattern for Glycosylphosphatidylinositol-anchored HDL-binding Protein 1 (GPIHBP1) in Mouse Tissues Revealed by Positron Emission Tomography Scanning. Journal of Biological Chemistry, 2010, 285, 39239-39248.	1.6	36
92	Minibody-Indocyanine Green Based Activatable Optical Imaging Probes: The Role of Short Polyethylene Glycol Linkers. ACS Medicinal Chemistry Letters, 2014, 5, 411-415.	1.3	35
93	Crossâ€Linkâ€Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications. Angewandte Chemie - International Edition, 2020, 59, 20552-20560.	7.2	35
94	Biodistribution and Radioimmunotherapy of Human Breast Cancer Xenografts with Radiometal-Labeled DOTA Conjugated Anti-HER2/neu Antibody 4D5. Bioconjugate Chemistry, 2000, 11, 327-334.	1.8	34
95	Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor. Sarcoma, 2012, 2012, 1-11.	0.7	34
96	Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development). Health Expectations, 2001, 4, 213-220.	1.1	33
97	Aligning physics and physiology: <scp>E</scp>ngineering antibodies for radionuclide delivery. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 693-714.	0.5	33
98	Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody. Theranostics, 2018, 8, 5903-5914.	4.6	33
99	Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Research, 2011, 1, 24.	1.1	31
100	Anti-carcinoembryonic Antigen Single-chain Variable Fragment Antibody Variants Bind Mouse and Human Neonatal Fc Receptor with Different Affinities That Reveal Distinct Cross-species Differences in Serum Half-life. Journal of Biological Chemistry, 2012, 287, 22927-22937.	1.6	30
101	Anti-MET ImmunoPET for Nonâ€“Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Molecular Cancer Therapeutics, 2014, 13, 2607-2617.	1.9	29
102	Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer. Clinical Cancer Research, 2014, 20, 6367-6378.	3.2	29
103	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics, 2019, 9, 5085-5104.	4.6	29
104	Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64â€“labeled daratumumab. Blood Advances, 2020, 4, 5194-5202.	2.5	29
105	A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptorâ€“Modified Hematopoietic Stem Cells for Cancer Therapy. Human Gene Therapy, 2019, 30, 413-428.	1.4	28
106	Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation. Protein Engineering, Design and Selection, 2014, 27, 317-324.	1.0	27
107	Partial cDNA sequence of the gamma subunit of transducin. Biochemical and Biophysical Research Communications, 1984, 124, 250-255.	1.0	26
108	Microfluidic-Based ¹⁸ F-Labeling of Biomolecules for Immunoâ€“Positron Emission Tomography. Molecular Imaging, 2011, 10, 7290.2010.00043.	0.7	26

#	Article	IF	Citations
109	A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 387-394.	0.7	25
110	A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments for ¹⁸F-Immuno-PET and Fluorescence Imaging. Journal of Nuclear Medicine, 2019, 60, 1467-1473.	2.8	24
111	Microfluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography. Molecular Imaging, 2011, 10, 168-76, 1-7.	0.7	24
112	Diabodies Targeting Epithelial Membrane Protein 2 Reduce Tumorigenicity of Human Endometrial Cancer Cell Lines. Clinical Cancer Research, 2008, 14, 7367-7377.	3.2	23
113	An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. Journal of Surgical Research, 2013, 185, 45-55.	0.8	23
114	Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine, 2018, 59, 410-417.	2.8	23
115	18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 489-500.	3.3	23
116	Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models. Clinical Cancer Research, 2019, 25, 188-200.	3.2	23
117	A mutation distal to the messenger RNA endpoint reduces transcription termination in the tryptophan operon in Escherichia coli. Journal of Molecular Biology, 1979, 133, 189-197.	2.0	22
118	Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 104-114.	3.3	22
119	An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive Tumors. Molecular Imaging and Biology, 2012, 14, 336-347.	1.3	22
120	A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Engineering, Design and Selection, 2015, 28, 307-316.	1.0	22
121	Dual transcript and protein quantification in a massive single cell array. Lab on A Chip, 2016, 16, 3682-3688.	3.1	22
122	In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement.. Blood, 2009, 114, 723-723.	0.6	22
123	Endocytosis and Intracellular Trafficking Properties of Transferrin-Conjugated Block Copolypeptide Vesicles. Biomacromolecules, 2013, 14, 1458-1464.	2.6	21
124	Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging. Molecular Imaging and Biology, 2017, 19, 656-664.	1.3	21
125	Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Medical Physics, 1995, 22, 2025-2027.	1.6	19
126	Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK. Nuclear Medicine and Biology, 2009, 36, 671-680.	0.3	18

#	Article	IF	Citations
127	Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging. Journal of Biomedical Optics, 2013, 18, 101304.	1.4	18
128	Engineering Multivalent Antibody Fragments for In Vivo Targeting. , 2004, 248, 209-226.		16
129	Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research, 2020, 10, 10.	1.1	16
130	ImmunoPET: harnessing antibodies for imaging immune cells. Molecular Imaging and Biology, 2022, 24, 181-197.	1.3	15
131	Molecular Imaging Probe Development Using Microfluidics. Current Organic Synthesis, 2011, 8, 473-487.	0.7	14
132	Positron Emission Tomography Imaging of Endometrial Cancer Using Engineered Anti-EMP2 Antibody Fragments. Molecular Imaging and Biology, 2013, 15, 68-78.	1.3	14
133	Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 10-15.	0.7	14
134	Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. BioProcess International, 2010, 8, 26-35.	2.0	14
135	An Official ATS Conference Proceedings: Advances in Small-Animal Imaging Application to Lung Pathophysiology. Proceedings of the American Thoracic Society, 2008, 5, 591-600.	3.5	13
136	CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. International Journal of Molecular Imaging, 2011, 2011, 1-9.	1.3	13
137	Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model. Scientific Reports, 2021, 11, 15384.	1.6	13
138	Protein Targeting Constructs in Alpha Therapy. Current Radiopharmaceuticals, 2011, 4, 197-213.	0.3	13
139	Development and characterization of an Î±vÎ²6-specific diabody and a disulfide-stabilized Î±vÎ²6-specific cys-diabody. Nuclear Medicine and Biology, 2015, 42, 945-957.	0.3	12
140	Tools for Pretargeted Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2001, 16, 103-108.	0.7	11
141	Construction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas. , 2003, 207, 351-364.		11
142	Rates and Equilibria for Probe Capture by an Antibody with Infinite Affinity. Bioconjugate Chemistry, 2010, 21, 784-791.	1.8	11
143	Levels of Murine, but Not Human, CXCL13 Are Greatly Elevated in NOD-SCID Mice Bearing the AIDS-Associated Burkitt Lymphoma Cell Line, 2F7. PLoS ONE, 2013, 8, e72414.	1.1	11
144	A Mutated Anti-CA19-9 scFv-Fc for Positron Emission Tomography of Human Pancreatic Cancer Xenografts. Molecular Imaging and Biology, 2014, 16, 721-729.	1.3	11

#	Article	IF	Citations
145	Improved Modeling of In Vivo Kinetics of Slowly Diffusing Radiotracers for Tumor Imaging. Journal of Nuclear Medicine, 2014, 55, 1539-1544.	2.8	11
146	Engineering A11 Minibody-Conjugated, Polypeptide-Based Gold Nanoshells for Prostate Stem Cell Antigen (PSCA)â€“Targeted Photothermal Therapy. SLAS Technology, 2017, 22, 26-35.	1.0	11
147	Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 258-265.	0.7	11
148	Characterization of a New Allele of the Human ERBB2 Gene by Allele-Specific Competition Hybridization. Genomics, 1993, 15, 426-429.	1.3	10
149	Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT. Journal of Experimental and Clinical Cancer Research, 2009, 28, 147.	3.5	10
150	Evaluation of Two Internalizing Carcinoembryonic Antigen Reporter Genes for Molecular Imaging. Molecular Imaging and Biology, 2011, 13, 526-535.	1.3	10
151	Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer. Molecular Imaging and Biology, 2020, 22, 1380-1391.	1.3	10
152	Blockade of epithelial membrane protein 2 (EMP2) abrogates infection ofChlamydia muridarummurine genital infection model. FEMS Immunology and Medical Microbiology, 2009, 55, 240-249.	2.7	9
153	Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. Blood Advances, 2021, 5, 5300-5311.	2.5	9
154	Genotype and phenotype: A practical approach to the immunogenetic analysis of lymphoproliferative disorders. Human Pathology, 1990, 21, 1132-1141.	1.1	8
155	A differential cell capture assay for evaluating antibody interactions with cell surface targets. Analytical Biochemistry, 2010, 401, 173-181.	1.1	8
156	On-demand radiosynthesis of N-succinimidyl-4-[¹⁸F]fluorobenzoate ([¹⁸F]SFB) on an electrowetting-on-dielectric microfluidic chip for ¹⁸F-labeling of protein. RSC Advances, 2019, 9, 32175-32183.	1.7	8
157	Tri-functional platform for construction of modular antibody fragments for in vivo¹⁸F-PET or NIRF molecular imaging. Chemical Science, 2020, 11, 1832-1838.	3.7	8
158	Biodistribution of Intra-Arterial and Intravenous Delivery of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles in a Rat Model to Guide Delivery Strategies for Diabetes Therapies. Pharmaceuticals, 2022, 15, 595.	1.7	8
159	Expression of Recombinant Antibodies in Mammalian Cell Lines. , 2004, 248, 255-268.		6
160	Characterization of a doubleâ€sided silicon strip detector autoradiography system. Medical Physics, 2015, 42, 575-584.	1.6	6
161	[89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model. Molecular Imaging and Biology, 2020, 22, 367-376.	1.3	6
162	Crossâ€Linkâ€Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications. Angewandte Chemie, 2020, 132, 20733-20741.	1.6	6

#	Article	IF	Citations
163	Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, e24160-e24160.	0.8	5
164	Numerical Comparison of Iodine-Based and Indium-Based Antibody Biodistributions. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 91-98.	0.7	4
165	Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies. Medical Physics, 2000, 27, 988-994.	1.6	3
166	Serial digital autoradiography with a silicon strip detector as a high resolution imaging modality for TRT dosimetry. , 2007, , .		2
167	Positron Emission Tomographic Imaging of Iodine 124 Antiâ€“Prostate Stem Cell Antigenâ€“Engineered Antibody Fragments in LAPC-9 Tumorâ€“Bearing Severe Combined Immunodeficiency Mice. Molecular Imaging, 2013, 12, 7290.2012.00033.	0.7	2
168	Generation of Single-Chain Fv Fragments and Multivalent Derivatives scFv-Fc and scFv-CH3 (Minibodies). , 2010, , 69-84.		2
169	In vivo veritas: Live phage display panning. Nature Biotechnology, 1996, 14, 429-431.	9.4	1
170	Recombination Activities of Escherichia coli RecA Protein: Synapsis and Strand Exchange. , 1983, , 535-548.		1
171	Concurrent Transcript and Protein Quantification in a Massive Single Cell Array Enables Population-Wide Observation of Oncogene Escape. Biophysical Journal, 2013, 104, 686a.	0.2	0
172	Molecular imaging in biology and pharmacology. , 2020, , 523-560.		0
173	Protein Engineering for Molecular Imaging. , 2021, , 753-770.		0
174	Molecular Imaging in Biology and Pharmacology. , 2008, , 457-XLV.		0
175	Imaging Tumor Xenografts Using Radiolabeled Antibodies. , 2010, , 491-506.		0
176	Sanjiv â€œSamâ€•Gambhir, MD, PhD: In Memoriam (1962â€“2020). Cancer Research, 2020, 80, 4305-4306.	0.4	0
177	Imaging the host response to cancer. , 2021, , .		0
178	89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNÎ± Fusion Protein in a Murine B-cell Lymphoma Model. Molecular Cancer Therapeutics, 2022, 21, 607-615.	1.9	0